Immix Biopharma announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMMX:
- Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
- Immix Biopharma 12 Month Review Progress Update
- Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
- Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
- Immix Biopharma: EC grants orphan drug designation to NXC-201